Download PDF
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry
Clementina López-Medina; Lucía Otero-Varela; Fernando Sánchez-Alonso; Vega Jovaní; Lorena Expósito-Pérez; Sheila Melchor-Díaz; Yanira Pérez-Vera; Paula Pretel-Ruiz; Javier Manero; Antonio Mera-Varela; Lourdes Mateo; Dolores Ruiz-Montesino; José Andrés Lorenzo-Martín; Teresa Pedraz-Penalva; Isabel Castrejón;
Reumatol Clin. 2025;21:
Patients with spondyloarthritis including psoriatic arthritis: Current needs, impact, and perspective
Estíbaliz Loza; Pedro Plazuelo; Ceade;
Reumatol Clin. 2023;19:273-8
Strategies and resources to optimise the management of Psoriatic Arthritis patients: The CREA Project
Raquel Almodóvar; Juan D. Cañete; Eduardo Collantes; Eugenio de Miguel; Cristina Fernández Carballido; Jordi Gratacós; Xavier Juanola; José A. Pinto; Rubén Queiro; Pedro Zarco;
Reumatol Clin. 2023;19:159-67